# A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid

> **NCT06221072** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Shanghai JMT-Bio Inc.** · enrollment: 1360 (estimated)

## Conditions studied

- Imaging Examination Shows at Least One Site With Bone Metastases From Soild Tumors

## Interventions

- **DRUG:** JMT103
- **DRUG:** zoledronic acid

## Key facts

- **NCT ID:** NCT06221072
- **Lead sponsor:** Shanghai JMT-Bio Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2024-04-05
- **Primary completion:** 2027-05-31
- **Final completion:** 2028-05-31
- **Target enrollment:** 1360 (ESTIMATED)
- **Last updated:** 2024-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06221072

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06221072, "A Study to Assess the Prevention of Bone-related Events in Patients With Bone Metastases From Malignant Solid Tumors Treated With JMT103 Compared to Zoledronic Acid". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT06221072. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*